DIASUNATE

This brand name is authorized in Nigeria.

Active ingredients

The drug DIASUNATE contains a combination of these active pharmaceutical ingredients (APIs):

1	Artesunate UNII 60W3249T9M - ARTESUNATE
	Artesunate is a semi-synthetic artemisinin derivative, indicated for the initial treatment of severe malaria in adults and children. The antimalarial mechanism of action of artesunate is generally thought to depend upon activation involving iron-mediated cleavage of the endoperoxide bridge of DHA to generate an unstable organic free radical followed by alkylation, where the free radical binds to malarial proteins leading to destruction of parasite membranes.
	Read more about Artesunate
2	Amodiaquine UNII K6PW2S574L - AMODIAQUINE HYDROCHLORIDE
	Read more about Amodiaquine

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
04-6911	Tablet	Diasunate Caplet TAB 100 mg; 270 mg	Each caplet contains: Artesunate 100 mg, and Amodiaquine (as Hydrochloride) 270 mg	28/09/2021
A11-0017	Granules	Diasunate Infant Granules ?? GRAN 25 mg; 75 mg 1 x 3's (in sachets)	Granules for Oral Suspension	29/03/2021
A11-0098	Powder	Diasunate Infant PWD 25 mg; 75 mg	Powder for reconstitution in sachets	29/03/2021
A11-0099	Powder	Diasunate Child PWD 50 mg; 150 mg	Powder for reconstitution in sachets	29/03/2021
A11-100247	Tablet	Diasunate Tablet TAB 25 mg; 67.5 mg		28/09/2021
A4-0243	Tablet	Diasunate Junior Tablet TAB 50 mg; 135 mg	Each tablet contains: Artesunate 50 mg, and Amodiaquine (as Hydrochloride) 135 mg	28/09/2021

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
P01BF03	Artesunate and amodiaquine	P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01B Antimalarials → P01BF Artemisinin and derivatives, combinations
Discover more medicines within P01BF03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	04-6911, A11-0017, A11-0098, A11-0099, A11-100247, A4-0243